加载中
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
常规交易时段
US$10.2457
+US$0.0657 · +0.65%
盘中时间采用ET。市场数据可能有所延迟。
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
日内区间
当前US$10.2457
52周区间
当前US$10.2457
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
81
深度低估
情绪
68
看涨
风险
51
风险偏高
动量
28
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
日内区间
当前US$10.2457
52周区间
当前US$10.2457
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.1亿 USD | 4.26亿 USD | 2.58亿 USD | 1.54亿 USD | 8094.3万 USD |
| 销货成本 | 2.17亿 USD | 2.07亿 USD | 1.69亿 USD | 1.19亿 USD | 7977万 USD |
| 毛利 | 2.93亿 USD | 2.2亿 USD | 8894.2万 USD | 3526.5万 USD | 117.3万 USD |
| 研究与开发 | 476.2万 USD | 181.3万 USD | 330万 USD | 361.4万 USD | 364.6万 USD |
| 销售、一般及管理费用 | 9158万 USD | 7412.4万 USD | 5902万 USD | 5245.8万 USD | 4289.7万 USD |
| 营业费用 | 1.01亿 USD | 8057万 USD | 6731万 USD | 7463万 USD | 5954.7万 USD |
| 利息收入 | 187.1万 USD | 209.7万 USD | 161.7万 USD | 4.48万 USD | 3.45万 USD |
| 利息支出 | 711万 USD | 1393万 USD | 2502.7万 USD | 1927.94万 USD | 1305.68万 USD |
| 折旧和摊销 | 809.6万 USD | 804.5万 USD | 833.2万 USD | 711.34万 USD | 549.55万 USD |
| 营业利润 | 1.91亿 USD | 1.39亿 USD | 2163.2万 USD | −3936.5万 USD | −5837.4万 USD |
| 净利润 | 1.47亿 USD | 1.98亿 USD | −2823.9万 USD | −6590.4万 USD | −7164.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$18.67
上涨空间 82.22%报告持有此股票敞口的交易所交易基金。
First Trust NYSE Arca Biotechnology Index FundFBT1.03亿3.57%28.91亿 USD0.55%US$259.88-1.53%
Vanguard Morningstar Total Stock Market ETFVTI6612.07万0.00%2.3万亿 USD0.03%US$380.74-0.22%
iShares Russell 2000 ETFIWM6011.3万0.08%787.4亿 USD0.19%US$276.07-0.66%
State Street SPDR S&P Biotech ETFXBI4624.76万0.47%103.03亿 USD0.35%US$148.2-2.11%
Vanguard Extended Market ETFVXF2523.45万0.03%954亿 USD0.05%US$232-0.65%
Vanguard Morningstar Small-Cap ETFVB2377.42万0.01%1853亿 USD0.03%US$286.94-0.42%
iShares Russell 2000 Growth ETFIWO2171.4万0.16%139.17亿 USD0.24%US$350.71-0.85%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2126.09万0.13%157.12亿 USD0.03%US$53.185-0.44%First Trust NYSE Arca Biotechnology Index FundFBTVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
